Who owns Kodiak Sciences Inc. (KOD)? Elite investor 13F holders
3 tracked elite investors reported holding Kodiak Sciences Inc as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | KODIAK SCIENCES INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 13245171.00 USD | 139717.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | KODIAK SCIENCES INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 8617320.00 USD | 90900.000000 | Shares | reduce | Original filing |
| Polen Capital Management | KODIAK SCIENCES INC | SHARE | 2026-09-30 | 2026-11-13 00:00:00 | 2298331.00 USD | 24244.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.